A recent report by IQVIA, “Advancing Biosimilar Sustainability in Europe,” offers a deep look inside the European Union’s biosimilars market, suggesting the current paradigm has raised questions of sustainability.
According to the report, the EU market to date includes more than 45 biosimilars for 15 biologic therapies for use in oncology, autoimmune disorders, diabetes and fertility.
While the expiration of patent protections for biologics has led to increased production of biosimilars and competition, there are some regulatory barriers obstructing the market’s full potential, the white paper states.
” … Some biosimilar policies and purchasing mechanisms limit participation of competitor products in specific markets, apply increasing price pressure or push physicians to switch patient product use,” the report states. “These current dynamics have raised questions about the sustainability of the biosimilars market in the long-term.”